PCOS Officially Renamed PMOS to Reflect Metabolic Nature
Polycystic Ovary Syndrome (PCOS) has been officially renamed Polyendocrine Metabolic Ovarian Syndrome (PMOS) following a 14-year global consultation. Announced at the European Congress of Endocrinology in Prague and published in The Lancet, the change aims to correct misleading terminology suggesting abnormal cysts, which recent studies confirm are not more prevalent in affected women. The new name better reflects the condition’s complex hormonal and metabolic impacts, affecting 170 million women worldwide. This update seeks to reduce stigma, improve diagnostic accuracy, and shift clinical focus toward systemic health risks like diabetes and cardiovascular disease.
Editorial summary awaiting refresh
Cross-source coverage
Wire timeline
PCOS Renamed to PMOS to Reflect Metabolic and Hormonal Impacts
Researchers announced on May 12, 2026, that Polycystic Ovary Syndrome (PCOS), the leading cause of infertility affecting 170 million women globally, is being renamed Polyendocrine Metabolic Ovarian Syndrome (PMOS). This change, detailed in The Lancet and presented at the European Congress of Endocrinology in Prague, aims to improve diagnosis, treatment, and patient understanding. The previous name often misled patients and clinicians into focusing on ovarian cysts, which are not always present, causing diagnostic delays. The new terminology better reflects the condition's broad hormonal and metabolic effects, including insulin resistance, cardiovascular risks, and mental health issues. The decision followed extensive consultation, including over 14,000 survey responses from patients and professionals, and input from 56 organizations led by the Androgen Excess and PCOS Society. While PMOS remains incurable, symptoms are manageable through medication and lifestyle changes. A three-year transition plan is underway to integrate the new term into clinical guidelines, health systems, and professional training worldwide.
The Straits Times World NewsPolycystic Ovary Syndrome (PCOS) Officially Renamed to PMOS
After 14 years of research and extensive global consultation, Polycystic Ovary Syndrome (PCOS) has been officially renamed Polyendocrine Metabolic Ovarian Syndrome (PMOS). This significant change was announced at the 8th European Congress of Endocrinology in Prague and published in The Lancet. Led by Professor Helena Teede from Monash University, the initiative aims to correct the misleading implication that the condition is primarily defined by ovarian cysts. Recent studies confirm that women with the syndrome do not have higher rates of abnormal cysts than the general population. The new name emphasizes the disorder's complex hormonal and metabolic nature, which affects approximately 170 million women worldwide and increases risks for type 2 diabetes, cardiovascular issues, and mental health challenges. Health experts believe this renaming will reduce misdiagnoses, encourage earlier intervention, and shift medical focus from purely reproductive symptoms to broader systemic health impacts. Patient advocates welcome the change, noting it validates their experiences and promotes a holistic approach to treatment. While diagnostic criteria remain largely unchanged, future guidelines may adjust ultrasound recommendations to reflect the updated understanding of the condition.
Just InPolycystic Ovary Syndrome (PCOS) Renamed to Polyendocrine Metabolic Ovarian Syndrome
Polycystic Ovary Syndrome (PCOS), a hormonal and metabolic condition affecting over 170 million women globally, has been officially renamed Polyendocrine Metabolic Ovarian Syndrome (PMOS). This change follows a 14-year global research effort led by Australian researchers to correct widespread misconceptions linking the syndrome to ovarian cysts. A recent study published in JAMA Internal Medicine, involving over 1,200 Finnish women, confirmed that individuals with the condition do not have higher rates of abnormal ovarian cysts compared to those without it. Experts emphasize that the previous name caused confusion, as the fluid-filled sacs associated with the condition are undeveloped egg follicles, not true cysts. The renaming aims to better reflect the systemic nature of the disorder, which impacts fertility, weight, mental health, and long-term risks for diabetes and heart disease. According to 2023 international guidelines, diagnosis no longer requires an ultrasound but relies on criteria such as irregular periods and high androgen levels. This landmark update seeks to improve clinical understanding and patient care by shifting focus from localized ovarian issues to the condition's broader endocrine and metabolic implications.
RNZ New Zealand HeadlinesPolycystic Ovary Syndrome (PCOS) Renamed Polyendocrine Metabolic Ovarian Syndrome (PMOS)
After more than a decade of global consultation involving international societies and patient groups, polycystic ovary syndrome (PCOS) has been officially renamed polyendocrine metabolic ovarian syndrome (PMOS). The announcement was made at the European Congress of Endocrinology in Prague and published in The Lancet. This change aims to better reflect the condition's complex nature, which affects not only the reproductive system but also metabolism, increasing risks for diabetes and cardiovascular disease. Experts argue that the previous term 'polycystic' was misleading, as it suggested the presence of abnormal cysts requiring surgery, whereas the condition involves eggs in arrested development. The renaming addresses decades of confusion and inadequate care caused by the outdated terminology. Led by endocrinologist Prof Helena Teede from Melbourne’s Monash Centre for Health Research & Implementation, the campaign incorporated patient perspectives to highlight the hormonal and metabolic realities of the disorder. PMOS affects approximately 170 million women worldwide, or one in eight. The new name is intended to reduce stigma, improve diagnostic accuracy, and provide hope for millions of women who have suffered from misdiagnosis and misunderstanding due to the previous nomenclature.
The GuardianPCOS Renamed PMOS to Reflect Metabolic and Endocrine Nature
A global panel of clinicians, researchers, and patient advocates has officially renamed Polycystic Ovary Syndrome (PCOS) to Polyendocrine Metabolic Ovarian Syndrome (PMOS). This change, published in The Lancet and presented at the European Congress of Endocrinology, aims to provide a more scientifically accurate description of the condition, which affects up to 13% of reproductive-age women. The previous name was criticized for being misleading, as many patients do not have ovarian cysts, leading to underdiagnosis and stigma. The renaming process spanned over a decade, involving surveys of nearly 22,000 stakeholders worldwide. While PMOS was chosen by a landslide vote to better reflect the endocrine and metabolic aspects of the disorder, some dissenting voices argued that retaining 'ovarian' excludes potential male manifestations of the syndrome. Despite these concerns, advocates emphasized the urgent need for an accurate name to improve diagnosis and care for women, avoiding further delays associated with debating male inclusion. The new terminology seeks to enhance communication, reduce stigma, and align medical understanding with the complex reality of the condition.
STATStudy Finds No Link Between PCOS and Higher Rate of Abnormal Ovarian Cysts
A new study published in JAMA Internal Medicine reveals that women with polycystic ovary syndrome (PCOS) do not have a higher rate of abnormal ovarian cysts compared to the general population, despite the condition's misleading name. The research, led by Professor Terhi Piltonen from the University of Oulu, analyzed data from 1,235 Finnish women, comparing ultrasounds of 223 women with PCOS against 1,012 without the condition. Results showed that while women with PCOS were significantly more likely to have multiple antral follicles, they did not exhibit increased rates of pathological or non-cancerous cysts. These findings support global efforts to rename the syndrome, as the current terminology causes unnecessary concern regarding cyst-related risks. Experts note that PCOS is a complex hormonal and metabolic disorder affecting approximately one in eight women, often leading to infertility, insulin resistance, and type 2 diabetes. The study suggests that women with PCOS do not require more frequent ultrasonography for cyst detection than those without the condition. Although the study had limitations, including a predominantly white European participant group, it confirms existing medical understanding that follicle count does not correlate with the cardio-metabolic effects of the disease.
Just In